The involvement of ILC2 cytokines such as IL-5 and IL-13 in the respiratory inflammation is quite extensive and thus, monoclonal antibodies targeting them are in clinical trials for the treatment of refractory asthma and CRS [80]. This evidence concerns the gene IL5 and congenital rubella syndrome.